The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of radiographic and pathologic outcomes in patients (pts) with advanced renal cell carcinoma (RCC) with and without thrombus receiving preoperative immune checkpoint inhibitor (ICI) regimens and circulating biomarkers.
 
Wadih Issa
No Relationships to Disclose
 
Damla Gunenc
No Relationships to Disclose
 
Song Zhang
No Relationships to Disclose
 
Qinhan Zhou
No Relationships to Disclose
 
Thomas Gerald
No Relationships to Disclose
 
Isamu Tachibana
No Relationships to Disclose
 
Raj Ramnik Bhanvadia
No Relationships to Disclose
 
Payal Kapur
No Relationships to Disclose
 
Solomon L. Woldu
Consulting or Advisory Role - Urogen pharma
 
Yair Lotan
Stock and Other Ownership Interests - C2i genomics; CAPs medical; Nanorobotics; Phinomics; Uroviu; Vessi Medical; Virtuoso Therapeutics
Consulting or Advisory Role - Abbvie; Ambu; AstraZeneca; Aura Biosciences; BMS; C2i genomics; caps medical; Cleveland Diagnostics; Convergent Genomics; Fergene; Merck; Nanogen Biopharmaceutical; Nanorobotics; Nucleix; pacific edge; phinomics; Photocure; Seagen; Stimit; Urogen pharma; uroviu; verity pharmaceuticals; Vessi Medical; virtuoso surgical; Xcures
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst); storz (Inst)
 
Jeffrey A. Cadeddu
Stock and Other Ownership Interests - EtiraRx; Levita Magnetics; OncoNano Inc
Consulting or Advisory Role - DeepQure; Distalmotion
 
Kris Gaston
No Relationships to Disclose
 
Qian Qin
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Exelixis
 
James Brugarolas
Consulting or Advisory Role - Exelixis; Johnson & Johnson; Telix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - U.S. Application Number: 17/153,128 “PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha” (Inst); U.S. Application Number: 17/206,895 “BIOMARKERS OF RESPONSE TO HIF-2alpha INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF” (Inst); U.S. Patent: US 11,576,889 B2 "METHODS OF IDENTIFYING AND TREATING PATIENTS WITH HIF-2 INHIBITOR RESISTANCE" (Inst)
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Andrew Zhuang Wang
Leadership - Archimmune Therapeutics; Capio BioSciences; Nanorobotics; Novartis (I)
Stock and Other Ownership Interests - Archimmune Therapeutics; Archimmune Therapeutics; Capio BioSciences
Consulting or Advisory Role - Aptitude Health (I); Aravive (I); AVEO (I); Bayer (I); Capio BioSciences; Dendreon (I); Eisai (I); Gerson Lehrman Group; Janssen (I); Kidney Cancer Association (I); Merck KGaA (I); Mirati Therapeutics (I); MJH Associates (I); Peerview (I); PlatformQ Health (I); QED Therapeutics (I); Regeneron (I); Sanofi/Aventis (I); Seagen (I)
Research Funding - Archimmune Therapeutics; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Biomatrix patent licensed to PhoenixSongs
Travel, Accommodations, Expenses - Exelixis (I); Genentech (I); Pfizer (I); Sanofi (I)
 
Vitaly Margulis
Honoraria - Blue Earth Diagnostics; Johnson & Johnson; Merck; Progenics; Steba Biotech
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; Exelixis; Janssen; Lilly; Merck; Pfizer; QED Therapeutics; Sanofi/Aventis; Seagen
Research Funding - Astellas Pharma; Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Janssen